No CrossRef data available.
Article contents
Characterization of Encapsulated Liposomal Irinotecan
Published online by Cambridge University Press: 05 August 2019
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Pharmaceuticals FIG – Imaging, Analysis, and Regulation of Medical Products, Devices and Data Integrity
- Information
- Copyright
- Copyright © Microscopy Society of America 2019
References
[3]Noble, CO, Kirpotin, DB, Hayes, ME, Mamot, C, Hong, K, Park, JW, Benz, CC, Marks, JD and Drummond, DC, Expert Opinion on Therapeutic Targets 8 (2004), p. 335.Google Scholar
[4]U.S. Food and Drug Administration. “Draft Guidance on Doxorubicin Hydrochloride.” https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM19 9635.pdf (Accessed 02.01.19).Google Scholar
[5]Drs. Noble and Jog, as well as L. Chen were supported in part by an appointment to the Research Participation Program at the Center for Drug Evaluation and Research administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and FDA. The authors would like to acknowledge the Advanced Characterization Facility at the FDA and CDRH/OSEL/DBCMS and CDER/OPQ/OTR for instrument use.Google Scholar
You have
Access